Brunsing Ryan L, Fowler Kathryn J, Yokoo Takeshi, Cunha Guilherme Moura, Sirlin Claude B, Marks Robert M
Department of Radiology, Stanford University, Stanford, CA 94305, USA.
Liver Imaging Group, Department of Radiology, University of California San Diego, San Diego, CA 92093, USA.
Hepatoma Res. 2020;6. doi: 10.20517/2394-5079.2020.50. Epub 2020 Sep 1.
This review focuses on emerging abbreviated magnetic resonance imaging (AMRI) surveillance of patients with chronic liver disease for hepatocellular carcinoma (HCC). This surveillance strategy has been proposed as a high-sensitivity alternative to ultrasound for identification of patients with early-stage HCC, particularly in patients with cirrhosis or obesity, in whom sonographic visualization of small tumors may be compromised. Three general AMRI approaches have been developed and studied in the literature - non-contrast AMRI, dynamic contrast-enhanced AMRI, and hepatobiliary phase contrast-enhanced AMRI - each comprising a small number of selected sequences specifically tailored for HCC detection. The rationale, general technique, advantages and disadvantages, and diagnostic performance of each AMRI approach is explained. Additionally, current gaps in knowledge and future directions are discussed. Based on emerging evidence, we cautiously recommend the use of AMRI for HCC surveillance in situations where ultrasound is compromised.
本综述聚焦于针对慢性肝病患者肝细胞癌(HCC)的新兴简化磁共振成像(AMRI)监测。该监测策略已被提议作为超声检查的一种高灵敏度替代方法,用于识别早期HCC患者,尤其是在肝硬化或肥胖患者中,这些患者小肿瘤的超声可视化可能会受到影响。文献中已开发并研究了三种通用的AMRI方法——非增强AMRI、动态对比增强AMRI和肝胆期对比增强AMRI——每种方法都包含少量专门为HCC检测量身定制的选定序列。文中解释了每种AMRI方法的原理、一般技术、优缺点及诊断性能。此外,还讨论了当前知识空白和未来方向。基于新出现的证据,我们谨慎建议在超声检查受限的情况下使用AMRI进行HCC监测。